Should durvalumab consolidation still be offered to Stage III NSCLC patients with PD-L1< 1%?

This is an extremely important question, but basing therapeutic decisions on this post-hoc, exploratory analysis is fraught with hazard. Still, the absence of OS benefit in this cohort (the HR heads in the wrong direction) gives me pause. For those with PD-L1 expression of 1% or higher, I enthusiast...

I believe so. As theMednet readers know, the preplanned analysis for PACIFIC included an analysis of those who had PDL1 greater or less than 25%, but further analysis (post-hoc, NOT pre-planned, and in my opinion not adequately powered) requested by regulatory authorities using a cutoff of 1% was pe...

In the PACIFIC trial, the primary endpoints were progression-free survival and overall survival in the intent-to-treat population. In a pre-planned subset analysis, PD-L1 expression was analyzed by at least 25% or less than 25%, and numerically more patients in the durvalumab arm had at least 25% PD...